Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325337 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
NCT01325337 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 307 participants.
The verdict
NCT01325337, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
Interventions
- DRUG bimatoprost vehicle solution
- DRUG bimatoprost Formulation A
- DRUG bimatoprost Formulation B
- DRUG bimatoprost Formulation C
- DRUG minoxidil 5% solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01325337
The ClinicalTrials.gov registry entry for NCT01325337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which bimatoprost vehicle solution is the first listed.
NCT01325337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01325337 about?
NCT01325337 is a clinical study titled "Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia". This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provi...
What is the current status of trial NCT01325337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2011-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01325337?
The interventions under investigation include: bimatoprost vehicle solution (DRUG), bimatoprost Formulation A (DRUG), bimatoprost Formulation B (DRUG), bimatoprost Formulation C (DRUG), minoxidil 5% solution (DRUG).
Who is sponsoring clinical trial NCT01325337?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.